# Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

> **NCT02070406** · PHASE1 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **BIOLOGICAL:** NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
- **BIOLOGICAL:** dendritic cell vaccine therapy
- **BIOLOGICAL:** aldesleukin
- **RADIATION:** fludeoxyglucose F 18
- **PROCEDURE:** positron emission tomography
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02070406
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-17
- **Primary completion:** 2018-12-18
- **Final completion:** 2018-12-18
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070406, "Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02070406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*